To investigate the in vitro and in vivo hypoglycemic function of composite solid beverage with extract of Malus hupehensis and Panax ginseng as the main raw material.

The in vitro hypoglycemic activity was evaluated by inhibiting the activity of α-amylase and α-glucosidase, the in vivo hypoglycemic activity was evaluated in mice with oral starch tolerance test and model of type 2 diabetes induced by high sugar and high fat diet combined with streptozotocin (STZ).

The composite solid beverage had a certain inhibitory effect on α-amylase and α-glucosidase activity, with semi-inhibitory concentration (IC₅₀) of (2.50±0.32) mg/mL and (0.36±0.03) mg/mL, respectively. In the oral starch tolerance test of normal mice, when the high and low dose composite solid beverage group compared with the blank control group, the amplitude of blood glucose increase at 30 min was reduced by 79.64% and 51.27% (P<0.05), respectively, the area under the blood glucose curve was decreased by 24.72% and 11.20% (P<0.05), respectively. After 4 weeks of drug administration in type 2 diabetic mice, when the high and low dose composite solid beverage group compared with the model group, the fasting blood glucose was decreased by 27.92% and 16.48% (P<0.05), respectively, glycosylated serum protein levels was decreased by 19.46% (P<0.05) and 8.60%, respectively, serum insulin levels was decreased by 28.84% and 18.57%(P<0.05), respectively, liver index was decreased by 13.59% (P<0.05) and 6.04%, respectively, kidney index was decreased by 18.67% (P<0.05) and 10.22%, respectively.

Malus hupehensis-Panax ginseng composite solid beverage has a good hypoglycemic activities in vitro and in vivo, which can significantly reduce postprandial and fasting blood glucose levels in mice, the mechanism may be related to inhibiting the activity of starch digestase,increasing insulin sensitivity and protecting liver and kidney tissue.